Rose hip exerts antidiabetic effects via a mechanism involving downregulation of the hepatic lipogenic program.
The aim of this study was to investigate the metabolic effects of a dietary supplement of powdered rose hip to C57BL/6J mice fed a high-fat diet (HFD). Two different study protocols were used; rose hip was fed together with HFD to lean mice for 20 wk (prevention study) and to obese mice for 10 wk (intervention study). Parameters related to obesity and glucose tolerance were monitored, and livers were examined for lipids and expression of genes and proteins related to lipid metabolism and gluconeogenesis. A supplement of rose hip was capable of both preventing and reversing the increase in body weight and body fat mass imposed by a HFD in the C57BL/6J mouse. Oral and intravenous glucose tolerance tests together with lower basal levels of insulin and glucose showed improved glucose tolerance in mice fed a supplement of rose hip compared with control mice. Hepatic lipid accumulation was reduced in mice fed rose hip compared with control, and the expression of lipogenic proteins was downregulated, whereas AMP-activated protein kinase and other proteins involved in fatty acid oxidation were unaltered. Rose hip intake lowered total plasma cholesterol as well as the low-density lipoprotein-to-high-density lipoprotein ratio via a mechanism not involving altered gene expression of sterol regulatory element-binding protein 2 or 3-hydroxymethylglutaryl-CoA reductase. Taken together, these data show that a dietary supplement of rose hip prevents the development of a diabetic state in the C57BL/6J mouse and that downregulation of the hepatic lipogenic program appears to be at least one mechanism underlying the antidiabetic effect of rose hip.
Division of Diabetes, Metabolism and Endocrinology, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.
Ulrika
U
Andersson
Emma
E
Henriksson
Kristoffer
K
Ström
Jan
J
Alenfall
Olga
O
Göransson
Cecilia
C
Holm
D052436:Adipose Tissue, White / Q000201:enzymology / Q000378:metabolism; D050154:Adiposity; D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D004041:Dietary Fats / Q000009:adverse effects; D019587:Dietary Supplements; D015536:Down-Regulation; D005234:Fatty Liver / Q000517:prevention & control*; D005260:Female; D018149:Glucose Intolerance / Q000517:prevention & control; D006937:Hypercholesterolemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050155:Lipogenesis; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000097:blood / Q000178:diet therapy* / Q000378:metabolism / Q000517:prevention & control*; D008517:Phytotherapy; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D027826:Rosa / Q000737:chemistry*
D019440:Anti-Obesity Agents; D004041:Dietary Fats; D007004:Hypoglycemic Agents; D012333:RNA, Messenger